QuidelOrtho (QDEL) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Teknova (TKNO) has outperformed QuidelOrtho (QDEL) over the past year, gaining 66.2% versus a loss of 55.6%. Over five years, TKNO leads with a -62.3% price change compared with -90.4% for QDEL. QuidelOrtho is the larger company by market cap ($809.2 million vs $451.5 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QDEL | TKNO |
|---|---|---|
| Share price | $11.80 | $8.41 |
| Market cap | $809.19M | $451.52M |
| 1-day change | -4.14% | -3.44% |
| YTD return | -56.90% | +129.21% |
| 1-year return | -55.58% | +66.22% |
| 5-year return | -90.40% | -62.29% |
| Forward P/E | 8.18 | — |
| EPS (TTM) | $-15.39 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.58 | $9.48 |
| 52-week low | $9.92 | $1.91 |
| Distance from 52-week high | -66.84% | -11.29% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +24.32% | +7.02% |
| Average volume | 1.49M | 230.99K |
| Shares outstanding | 68.58M | 53.69M |
| Employees | 6,500 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TKNO has outperformed QDEL by 121.8 percentage points over the past year.
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
QDEL vs TKNO FAQ
Which is bigger, QuidelOrtho or Alpha Teknova?
QuidelOrtho (QDEL) is larger, with a market capitalization of $809.19M compared with $451.52M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, QDEL or TKNO?
TKNO returned +66.22% over the past 12 months, compared with -55.58% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are QuidelOrtho and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.